Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 June 2007, Vol. 109, No. 12, pp. 5160-5163.
Prepublished online as a Blood First Edition Paper on March 5, 2007; DOI 10.1182/blood-2006-12-063594.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-12-063594v1
109/12/5160    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neelapu, S. S.
Right arrow Articles by Kwak, L. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neelapu, S. S.
Right arrow Articles by Kwak, L. W
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted December 19, 2006
Accepted February 26, 2007

A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma

Sattva S. Neelapu*, Barry L Gause, Linda Harvey, Seung-Tae Lee, Andrea Robin Frye, Jessie Horton, Richard J Robb, Mircea C Popescu, and Larry W Kwak

Experimental and Transplantation Immunology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, United States
SAIC, NCI at Frederick, Frederick, MD, United States
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Biomira USA Inc., Cranbury, NJ, United States
XEME Biopharma Inc., Plainsboro, NJ, United States

* Corresponding author; email: sneelapu{at}mdanderson.org.

Clinical studies suggest that treatment with vaccines comprised of idiotype protein may be associated with improved clinical outcome in follicular lymphoma patients. However, the time-consuming process required to generate patient-specific vaccines is a major limitation. Here, we report results of a pilot clinical trial with a novel autologous, tumor-derived proteoliposome vaccine formulation that could be rapidly produced within a single day. Vaccination was safe, induced autologous tumor-specific type 1 cytokine responses in 5 out of 10 follicular lymphoma patients, and was associated with induction of a sustained complete response in one patient. Other patients had large tumor burdens and progressed after a median duration of 8 months. These results suggest that further testing of this vaccine formulation, particularly in the setting of minimal disease is warranted. Furthermore, the proteoliposome formulation may provide a model for vaccine development for other human cancers, for which tumor-associated antigens need not be defined.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 ASH Education BookHome page
S. S. Neelapu and L. W. Kwak
Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies
Hematology, January 1, 2007; 2007(1): 243 - 249.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020